What Researchers Did
Researchers conducted a retrospective study of 44 cancer patients with malignant bowel obstruction from peritoneal spread, comparing 30 who received daily HBOT at 2.5 ATA for 60 minutes against 14 who did not.
What They Found
Significantly more HBOT patients resumed eating compared to the non-HBOT group. The proportion with unresolved obstruction was significantly higher in the non-HBOT group. Overall survival was significantly longer in the HBOT group, even among patients who could not have surgery.
What This Means for Canadian Patients
For Canadian cancer patients with bowel obstruction from peritoneal spread who cannot have surgery, HBOT may improve quality of life by restoring the ability to eat and extending survival. This is a palliative care context where few effective options exist.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
This is a small retrospective study from a single Japanese center, limiting generalizability and introducing potential selection bias in who received HBOT.